Crispr Therapeutics AG (CRSP)
Why Is CRISPR Therapeutics (CRSP) Up 12% Since Last Earnings Report?
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock?
CRISPR Therapeutics AG (CRSP) Jefferies 2024 Global Healthcare Conference (Transcript)
CRISPR Therapeutics AG (NASDAQ:CRSP ) Jefferies 2024 Global Healthcare Conference June 5, 2024 10:00 AM ET Company Participants Samarth Kulkarni - Chief Executive Officer Conference Call Participants Maury Raycroft - Jefferies Maury Raycroft Good morning. My name is Maury Raycroft and I'm one of the biotech analysts at Jefferies.
Cathie Wood Is Buying the Dip on These 2 Biotech Stocks. Should You?
Buying the dip in a promising stock can be an effective strategy. CRISPR Therapeutics has a long way to go before becoming profitable.
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
3 Reasons to Buy CRISPR Therapeutics Stock Like There's No Tomorrow
CRISPR Therapeutics is in the process of launching its first medicine. It has plenty of cash, no debt, and manageable expenses.
Is CRISPR Therapeutics a Millionaire Maker?
CRISPR Therapeutics is finally at the cusp of profitability. Its pipeline has quite a few promising opportunities beyond the approved therapies.
Bull Market Buys: 2 Growth Stocks to Own for the Long Run
Indexes are extending bull market gains, reaching new records. It's not too late to get in on the action -- history suggests this bull market could have much farther to go.
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by National Bank of Canada FI
National Bank of Canada FI lessened its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 63.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 668 shares of the company’s stock after selling 1,170 shares during the quarter. National Bank of Canada FI’s holdings in CRISPR Therapeutics were worth $44,000 as of its most recent filing with the SEC. Other large investors have also modified their holdings of the company. Vestmark Advisory Solutions Inc. acquired a new stake in CRISPR Therapeutics during the fourth quarter valued at approximately $10,848,000. Axxcess Wealth Management LLC lifted its stake in CRISPR Therapeutics by 16.2% during the fourth quarter. Axxcess Wealth Management LLC now owns 9,040 shares of the company’s stock worth $566,000 after purchasing an additional 1,259 shares during the last quarter. JFG Wealth Management LLC acquired a new position in CRISPR Therapeutics in the fourth quarter worth $220,000. Seaview Investment Managers LLC bought a new stake in CRISPR Therapeutics during the fourth quarter valued at $275,000. Finally, Mach 1 Financial Group LLC acquired a new stake in shares of CRISPR Therapeutics during the fourth quarter worth $441,000. Institutional investors own 69.20% of the company’s stock. Wall Street Analyst Weigh In CRSP has been the subject of a number of recent research reports. Chardan Capital boosted their price objective on shares of CRISPR Therapeutics from $110.00 to $112.00 and gave the company a “buy” rating in a research report on Thursday, February 22nd. Royal Bank of Canada increased their price target on CRISPR Therapeutics from $57.00 to $66.00 and gave the stock a “sector perform” rating in a research report on Thursday, February 22nd. JMP Securities reissued a “market outperform” rating and issued a $86.00 price target on shares of CRISPR Therapeutics in a report on Thursday, May 9th. Oppenheimer dropped their target price on CRISPR Therapeutics from $102.00 to $95.00 and set an “outperform” rating on the stock in a research report on Friday, May 10th. Finally, Robert W. Baird boosted their price target on shares of CRISPR Therapeutics from $46.00 to $52.00 and gave the company a “neutral” rating in a report on Thursday, May 9th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, CRISPR Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $73.93. View Our Latest Report on CRSP Insider Buying and Selling In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 1,913 shares of CRISPR Therapeutics stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $79.67, for a total transaction of $152,408.71. Following the transaction, the general counsel now owns 57,371 shares of the company’s stock, valued at approximately $4,570,747.57. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, General Counsel James R. Kasinger sold 1,913 shares of CRISPR Therapeutics stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $79.67, for a total transaction of $152,408.71. Following the completion of the sale, the general counsel now directly owns 57,371 shares in the company, valued at approximately $4,570,747.57. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Samarth Kulkarni sold 6,370 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $79.67, for a total transaction of $507,497.90. Following the transaction, the chief executive officer now directly owns 194,257 shares in the company, valued at approximately $15,476,455.19. The disclosure for this sale can be found here. In the last ninety days, insiders sold 63,992 shares of company stock valued at $4,525,135. Corporate insiders own 4.10% of the company’s stock. CRISPR Therapeutics Stock Performance Shares of NASDAQ:CRSP opened at $56.22 on Monday. The company has a market capitalization of $4.77 billion, a PE ratio of -20.67 and a beta of 1.80. The stock has a fifty day moving average of $62.11 and a 200-day moving average of $65.55. CRISPR Therapeutics AG has a one year low of $37.55 and a one year high of $91.10. CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($1.43) EPS for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.08). The business had revenue of $0.50 million for the quarter, compared to the consensus estimate of $25.53 million. The company’s quarterly revenue was down 99.5% on a year-over-year basis. During the same period in the previous year, the company earned ($0.67) earnings per share. As a group, research analysts forecast that CRISPR Therapeutics AG will post -5.64 EPS for the current fiscal year. CRISPR Therapeutics Profile (Free Report) CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
Is CRISPR Therapeutics Stock a Buy?
CRISPR develops cutting-edge therapies that could be transformative. The gene-editing specialist has launched its first approved treatment.
